DDC and Parkinson disease: A little-known fact is that peripheral inhibition of dopa decarboxylase, as is routinely used in the treatment of PD, diverts more levodopa into the catechol O-methyltransferase pathway and so elevates plasma levels of 3-0MD even further (Dingemanse et al. 1997).